阿西替尼(Axitinib)

[Indications] Axitinib is used for adult patients with advanced renal cell carcinoma (RCC) who have failed a previous tyrosine kinase inhibitor or cytokine therapy.

[Dosage and Administration] The recommended dose of Axitinib is 5 mg twice a day, with an interval of 12 hours between doses.
Treatment should be continued as long as clinical benefit is observed, or until unacceptable toxicity occurs, which cannot be controlled by concomitant medication or dose adjustment.
If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken as usual.

[Adverse Reactions] There is a risk of the following adverse reactions: hypertension, arterial thromboembolic events, venous thromboembolic events, bleeding, heart failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevated liver enzymes, liver damage and fetal development.

[Storage] Store below 25 degrees Celsius away from light.

[Manufacturer]
Axitinib is developed and produced by Pfizer Pharmaceuticals in the United States